Lee, Yunjin
Robbins, Nicole
Cowen, Leah E.
Funding for this research was provided by:
Gouvernement du Canada|Canadian Institutes of Health Research (FDN-154288)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01AI1654661)
Article History
Received: 27 February 2023
Accepted: 17 May 2023
First Online: 17 July 2023
Competing interests
: L.E.C. is a co-founder and shareholder in Bright Angel Therapeutics, a platform company for development of novel antifungal therapeutics. L.E.C. is a Science Advisor for Kapoose Creek, a company that harnesses the therapeutic potential of fungi. The remaining authors declare no competing interests.